Print Page  |  Close Window

SEC Filings

TEVA PHARMACEUTICAL INDUSTRIES LTD filed this Form 8-K on 02/08/2018
Entire Document

Exhibit 99.1

Teva Reports 2017 Full Year and Fourth Quarter Financial Results

JERUSALEM--(BUSINESS WIRE)--February 8, 2018--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the year and the quarter ended December 31, 2017.


FY 2017

Q4 2017

Revenues $22.4 billion $5.5 billion
Cash flow from operations $3.5 billion $1.2 billion
GAAP earnings (loss) per share ($16.26) ($11.41)
Non-GAAP EPS $4.01 $0.93

2018 Business outlook:

  • Revenues are expected to be $18.3 - 18.8 billion
  • Non-GAAP EPS is expected to be $2.25-2.50

Kåre Schultz, Teva’s President and CEO, said, “2017 was a challenging year for Teva. Starting 2018 we are focused on meeting our financial obligations and ensuring a much more solid and sustainable business model going forward. We are making strong progress on the restructuring plan, and I am optimistic about the progress made and remain confident in our ability to deliver on our targets in the coming year.

Teva remains a recognized world-class leader in global healthcare, delivering unique value through accessible treatments and innovative medicines. By improving our financial profile through stabilization of our operating profit and cash flow, we will be better positioned to continue serving patients worldwide.”